Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Patients rate their symptoms after starting secukinumab for hidradenitis suppurativa

NCT ID NCT06444087

Knowledge-focused Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows 192 adults with hidradenitis suppurativa (a painful skin condition) who are starting secukinumab as part of their normal care. Researchers will ask patients to rate their pain, oozing, and bad smell after 12 months. The goal is to understand how the drug affects symptoms from the patient's point of view, not to test a new treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
secukinumab
What this could lead to
If successful, this study could show how well secukinumab works from the patient's perspective, helping doctors better understand its real-world benefits for hidradenitis suppurativa.
What could go wrong
This is an observational study, not a controlled trial, so results may be influenced by factors other than the drug. It only follows patients for 12 months and does not test a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

192 people

The number who actually took part.

Started

Jun 2024

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population will include male and female patients (aged ≥ 18 years) with a diagnosis of HS and for whom the decision to initiate treatment with secukinumab was made independently of the study.

Ages

18 to 99 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Male and female patients ≥ 18 years old, 2. Patients who do not object to participation in the study, 3. Diagnosis of HS clinically confirmed, 4. Initiation of secukinumab treatment for HS in compliance with the summary of product characteristics, 5. The physician's decision to initiate secukinumab has been taken according to his/her own practice and regardless of study participation. Exclusion Criteria: 1. Patients with any medical or psychological condition which, in the physician's opinion, may prevent participation in the study, 2. Patients participating in a clinical trial.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hidradenitis suppurativa are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hidradenitis suppurativa

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hidradenitis suppurativa

Contacts and locations

Locations

  • Novartis Investigative Site

    Nice, France, 06000, France

  • Novartis Investigative Site

    Antony, 92160, France

  • Novartis Investigative Site

    Bordeaux, 33075, France

  • Novartis Investigative Site

    Brest, 29609, France

  • Novartis Investigative Site

    Calais, 62100, France

  • Novartis Investigative Site

    Dijon, 21000, France

  • Novartis Investigative Site

    La Rochelle, 17019, France

  • Novartis Investigative Site

    Le Mans, 72000, France

  • Novartis Investigative Site

    Lille, 59037, France

  • Novartis Investigative Site

    Lorient, 56322, France

  • Novartis Investigative Site

    Lyon, 69003, France

  • Novartis Investigative Site

    Marseille, 13008, France

  • Novartis Investigative Site

    Martigues, 13500, France

  • Novartis Investigative Site

    Montpellier, 34090, France

  • Novartis Investigative Site

    Nantes, 44093, France

  • Novartis Investigative Site

    Paris, 75014, France

  • Novartis Investigative Site

    Rodez, 12000, France

  • Novartis Investigative Site

    Rouen, 76031, France

  • Novartis Investigative Site

    Saint-Mandé, 94160, France

  • Novartis Investigative Site

    Saint-Pierre, 97410, France

  • Novartis Investigative Site

    Toulouse, 31400, France

  • Novartis Investigative Site

    Vannes, 56000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.